Literature DB >> 6413479

The role of Pseudomonas aeruginosa in infections.

H C Neu.   

Abstract

Pseudomonas aeruginosa, an organism ubiquitous in nature, has assumed an increasingly prominent role as the aetiological agent in serious infections in hospitalized patients. Pseudomonas has a number of pathogenic properties, which include its capsule, exotoxin A and various proteases. Although normal individuals infrequently carry this organism as part of their flora, patients with burns, malignancy, and after surgery often are colonized and subsequently infected with Pseudomonas. Infections produced by Pseudomonas include bacteraemia, respiratory infection, urinary tract infection, osteomyelitis, and infections of burns and soft tissues. Because of the resistance properties of Pseudomonas, therapy has been difficult. However, the development of highly effective antipseudomonas penicillins has brightened the picture. Nonetheless great progress can still be made in control and prevention of serious Pseudomonas infection.

Entities:  

Mesh:

Year:  1983        PMID: 6413479     DOI: 10.1093/jac/11.suppl_b.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice.

Authors:  Y Hirakata; M Kaku; K Tomono; K Tateda; N Furuya; T Matsumoto; R Araki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Characterization of a protein from normal human polymorphonuclear leukocytes with bactericidal activity against Pseudomonas aeruginosa.

Authors:  C J Hovde; B H Gray
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

Review 3.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

4.  Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.

Authors:  K Tateda; Y Ishii; T Matsumoto; N Furuya; M Nagashima; T Matsunaga; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Structural gene and complete amino acid sequence of Pseudomonas aeruginosa IFO 3455 elastase.

Authors:  J Fukushima; S Yamamoto; K Morihara; Y Atsumi; H Takeuchi; S Kawamoto; K Okuda
Journal:  J Bacteriol       Date:  1989-03       Impact factor: 3.490

6.  Physiological effects of a bactericidal protein from human polymorphonuclear leukocytes on Pseudomonas aeruginosa.

Authors:  C J Hovde; B H Gray
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

7.  Selective medium for Pseudomonas aeruginosa that uses 1,10-phenanthroline as the selective agent.

Authors:  J K Keeven; B T DeCicco
Journal:  Appl Environ Microbiol       Date:  1989-12       Impact factor: 4.792

8.  Revised pyocin typing method for Pseudomonas aeruginosa.

Authors:  J A Fyfe; G Harris; J R Govan
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

9.  Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa.

Authors:  K Tateda; Y Hirakata; N Furuya; A Ohno; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibiotics.

Authors:  G T Mai; J G McCormack; W K Seow; G B Pier; L A Jackson; Y H Thong
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.